With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

Sharp rise in cases over 30 years compounded by millions of people lacking access to medication, Lancet study finds ...

"While GLP-1-based therapies have revolutionized patient care for obesity ... In 2023, Embark Biotech was acquired by Novo Nordisk to develop next generation therapeutics for cardiometabolic disease.

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

The use of this peptide-based GLP-1/glucagon dual receptor agonist is currently being explored in the ongoing phase 2b IMPACT ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...